Rutherford, Boyle Introduce Lung Cancer Legislation
Resolution would designate November as Lung Cancer Awareness Month
WASHINGTON, D.C. -- Today, Congressmen John Rutherford (FL-04) and Brendan F. Boyle (PA-02), bipartisan co-chairs of the Congressional Lung Cancer Caucus, introduced legislation to designate November as Lung Cancer Awareness Month. While Lung Cancer Awareness Month has traditionally taken place in November, this legislation in Congress would formally recognize its observance during that month.
"As co-chair of the Lung Cancer Caucus and a member of the House Appropriations Committee, I am committed to supporting investments in lung cancer research and development," said Congressman Rutherford. "While we have made significant progress, lung cancer continues to account for more deaths than colon cancer, breast cancer, and prostate cancer combined. This resolution designating November as Lung Cancer Awareness Month seeks to increase detection and diagnosis of lung cancer by promoting the awareness, availability, and importance of early screening. Thank you to Congressman Boyle for partnering with me to lead this important effort."
"Lung cancer continues to be one of the leading causes of death among Americans, especially for young women and veterans," said Congressman Boyle. "Recognizing November as Lung Cancer Awareness month is a step toward raising greater awareness and increasing the odds for early detection, which is known to increase the survival rate. As co-chair of the Lung Cancer Caucus, I'll continue fighting for the hundreds of thousands of Americans impacted by lung cancer by combatting the stigma and increasing federal funds for better research and treatment."
Lung cancer is the second most common cancer and is a leading cause of death in the United States. Each year more people die of lung cancer than colon, breast, and prostate cancer combined. The bipartisan Congressional Lung Cancer Caucus helps educate and inform Members of Congress on issues specifically related to eliminating the stigma, reducing mortality, improving survivorship, furthering research, and ensuring equitable access to preventive screening, treatments, diagnostics and testing of lung cancer.